CA2840373A1 - Compounds and methods of prophylaxis and treatment regarding nicotinic receptor antagonists - Google Patents

Compounds and methods of prophylaxis and treatment regarding nicotinic receptor antagonists Download PDF

Info

Publication number
CA2840373A1
CA2840373A1 CA2840373A CA2840373A CA2840373A1 CA 2840373 A1 CA2840373 A1 CA 2840373A1 CA 2840373 A CA2840373 A CA 2840373A CA 2840373 A CA2840373 A CA 2840373A CA 2840373 A1 CA2840373 A1 CA 2840373A1
Authority
CA
Canada
Prior art keywords
disease
disorder
impaired
compounds
receptor antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2840373A
Other languages
English (en)
French (fr)
Inventor
Youyi Peng
Lawrence P. Wennogle
Qiang Zhang
John Tomesch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intra Cellular Therapies Inc
Original Assignee
Intra Cellular Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intra Cellular Therapies Inc filed Critical Intra Cellular Therapies Inc
Publication of CA2840373A1 publication Critical patent/CA2840373A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2840373A 2011-06-24 2012-06-22 Compounds and methods of prophylaxis and treatment regarding nicotinic receptor antagonists Abandoned CA2840373A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/US2011/041866 WO2012177263A1 (en) 2011-06-24 2011-06-24 Compounds and methods of prophylaxis and treatment regarding nictonic receptor antagonists
USPCT/US2011/041866 2011-06-24
US201161501207P 2011-06-25 2011-06-25
US61/501,207 2011-06-25
PCT/US2012/043813 WO2012178057A1 (en) 2011-06-24 2012-06-22 Compounds and methods of prophylaxis and treatment regarding nictonic receptor antagonists

Publications (1)

Publication Number Publication Date
CA2840373A1 true CA2840373A1 (en) 2012-12-27

Family

ID=47422974

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2840373A Abandoned CA2840373A1 (en) 2011-06-24 2012-06-22 Compounds and methods of prophylaxis and treatment regarding nicotinic receptor antagonists
CA2840047A Abandoned CA2840047A1 (en) 2011-06-24 2012-06-22 Organic compounds

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2840047A Abandoned CA2840047A1 (en) 2011-06-24 2012-06-22 Organic compounds

Country Status (13)

Country Link
US (4) US9108949B2 (https=)
EP (1) EP2723173B1 (https=)
JP (1) JP6087911B2 (https=)
KR (1) KR20140036305A (https=)
CN (1) CN103717069B (https=)
AU (2) AU2012272646B2 (https=)
BR (1) BR112013033306A2 (https=)
CA (2) CA2840373A1 (https=)
ES (1) ES2627338T3 (https=)
IL (1) IL230036A (https=)
MX (1) MX342322B (https=)
RU (1) RU2610094C2 (https=)
WO (3) WO2012177263A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012177263A1 (en) * 2011-06-24 2012-12-27 Intra-Cellular Therapies, Inc. Compounds and methods of prophylaxis and treatment regarding nictonic receptor antagonists
US11491150B2 (en) 2017-05-22 2022-11-08 Intra-Cellular Therapies, Inc. Organic compounds
WO2019152680A1 (en) * 2018-01-31 2019-08-08 Flagship Pioneering Innovations V, Inc. Methods and compositions for treating cancer using chrna6 inhibitors
US12396992B2 (en) 2019-01-07 2025-08-26 Intra-Cellular Therapies, Inc. Organic compounds
WO2021008565A1 (zh) * 2019-07-16 2021-01-21 清华大学 乙酰胆碱通路调节剂在治疗癌症中的用途
AU2020343329C1 (en) 2019-09-03 2026-02-12 Intra-Cellular Therapies, Inc. Methods of treatment
EP4238970A1 (en) * 2022-03-03 2023-09-06 InterAx Biotech AG Modulators of ackr3 and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6953855B2 (en) * 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
PE20021019A1 (es) * 2001-04-19 2002-11-13 Upjohn Co Grupos azabiciclicos sustituidos
AU2002363250A1 (en) * 2001-11-01 2003-05-12 Icagen, Inc. Pyrazole-amides and-sulfonamides
WO2004039815A2 (en) * 2002-11-01 2004-05-13 Pharmacia & Upjohn Company Llc Compounds having both alpha7 nachr agonist and 5ht antagonist activity for treatment of cns diseases
WO2004064836A2 (en) 2003-01-22 2004-08-05 Pharmacia & Upjohn Company Llc Treatment of diseases with alpha-7 nach receptor full agonists
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
US20040220170A1 (en) 2003-05-01 2004-11-04 Atkinson Robert N. Pyrazole-amides and sulfonamides as sodium channel modulators
JP2006525355A (ja) * 2003-05-01 2006-11-09 アボット・ラボラトリーズ ナトリウムチャンネルモジュレーターとしてのピラゾール−アミドおよびスルホンアミド
EP1638944A1 (en) * 2003-06-12 2006-03-29 Eli Lilly And Company Tachykinin receptor antagonists
US20110060017A1 (en) 2008-03-11 2011-03-10 Neurosearch A/S Novel 1,2,3-triazole derivatives useful as modulators of nicotinic acetylcholine receptors
US20100179186A1 (en) 2008-10-10 2010-07-15 University Of Kentucky Research Foundation USE OF A NOVEL ALPHA-7 nAChR ANTAGONIST TO SUPPRESS PATHOGENIC SIGNAL TRANSDUCTION IN CANCER AND AIDS
WO2012177263A1 (en) 2011-06-24 2012-12-27 Intra-Cellular Therapies, Inc. Compounds and methods of prophylaxis and treatment regarding nictonic receptor antagonists

Also Published As

Publication number Publication date
MX2014000255A (es) 2014-08-21
MX342322B (es) 2016-09-23
EP2723173A4 (en) 2015-02-18
KR20140036305A (ko) 2014-03-25
WO2012178057A1 (en) 2012-12-27
JP2014517078A (ja) 2014-07-17
CN103717069A (zh) 2014-04-09
US9108949B2 (en) 2015-08-18
WO2012177263A1 (en) 2012-12-27
ES2627338T3 (es) 2017-07-27
AU2012272680A1 (en) 2014-02-20
US20140205595A1 (en) 2014-07-24
EP2723173A1 (en) 2014-04-30
US20160008343A1 (en) 2016-01-14
JP6087911B2 (ja) 2017-03-01
US9452160B2 (en) 2016-09-27
CA2840047A1 (en) 2012-12-27
US9708294B2 (en) 2017-07-18
US20140205596A1 (en) 2014-07-24
BR112013033306A2 (pt) 2016-08-16
IL230036A (en) 2016-10-31
US20160237061A1 (en) 2016-08-18
AU2012272646A1 (en) 2014-02-20
US9469625B2 (en) 2016-10-18
CN103717069B (zh) 2018-06-05
RU2610094C2 (ru) 2017-02-07
RU2014102191A (ru) 2015-07-27
AU2012272646B2 (en) 2016-09-08
WO2012178112A1 (en) 2012-12-27
EP2723173B1 (en) 2017-04-19

Similar Documents

Publication Publication Date Title
US9452160B2 (en) Compounds and methods of prophylaxis and treatment regarding nicotinic receptor antagonists
Wang et al. Targeting Bruton's tyrosine kinase with ibrutinib in B‐cell malignancies
CA3151507C (en) Use of pridopidine for treating functional decline
WO2010132423A1 (en) Treatment of cognitive disorders with certain alpha-7 nicotinic acid receptors in combination with acetylcholinesterase inhibitors
Holman In defense of secondary pharmaceutical patents: A response to the UN's guidelines for pharmaceutical patent examination
Sanders et al. Stoichiometry-selective antagonism of α4β2 nicotinic acetylcholine receptors by fluoroquinolone antibiotics
Cunningham et al. Multiple nicotine training doses in mice as a basis for differentiating the effects of smoking cessation aids
Peng et al. Discovery of novel α7 nicotinic receptor antagonists
Xu et al. Advances in cancer chemotherapeutic drug research in China
Liang et al. Progress in the study of mefloquine as an antibiotic adjuvant for combination bacterial inhibition treatment
Cieslik et al. Wiero nska, JM Serotonergic–muscarinic interaction within the prefrontal cortex as a novel target to reverse schizophrenia-related cognitive symptoms
Yoshikawa et al. The broad‐spectrum anti‐emetic activity of AS‐8112, a novel dopamine D2, D3 and 5‐HT3 receptors antagonist
Reiss et al. The nociceptin orphanin FQ peptide receptor agonist, Ro64-6198, impairs recognition memory formation through interaction with glutamatergic but not cholinergic receptor antagonists
Lan et al. Chemical space of FLT3 inhibitors as potential anti-AML drugs
Yeom et al. Tripterygium-derived celastrol inhibits 5-HT3A receptors via key residue interactions: A comparative electrophysiological and docking study
Carroll et al. 4β-Methyl-5-(3-hydroxyphenyl) morphan opioid agonist and partial agonist derived from a 4β-methyl-5-(3-hydroxyphenyl) morphan pure antagonist
Toma et al. Neuronal nicotinic acetylcholine receptor agonists
Li et al. The discovery of risperidone: a case of multiple target antipsychotic drug
O'Callaghan et al. Discovery of Novel alpha7 Nicotinic Receptor Antagonists
JP2020507609A (ja) アルコール使用障害の治療
Sousa Targeting cancer-related proteins: Rational design of covalent inhibitors and degraders for TEC kinases and serine hydrolases
Huang et al. 12Advances in Cancer Chemotherapeutic Drug Research in China
HK40042967B (zh) 作为d-氨基酸氧化酶抑制剂的已知化合物的用途
Daniely et al. P. 1. c. 055 Metadoxine: a novel 5HT-2B receptor antagonist with a possible therapeutic role in treating ADHD
Horton Discovery of GZ-793A, a Novel VMAT2 Inhibitor and Potential Pharmacotherapy for Methamphetamine Abuse

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20170622

R00 Party data change recorded

Free format text: ST27 STATUS EVENT CODE: T-6-6-R10-R00-R113 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF ADDRESS OR METHOD OF CORRESPONDENCE REQUEST RECEIVED

Effective date: 20241128

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: T-6-6-R10-R18-R143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF ADDRESS REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260413

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: T-6-6-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260413